| 495 | 0 | 126 |
| 下载次数 | 被引频次 | 阅读次数 |
慢性阻塞性肺疾病（COPD）是一种以持续呼吸道症状和气流受限为特征的异质性肺部疾病。我国有近1亿的COPD患者，该疾病的死亡率较高。吸入制剂作为COPD治疗的一线选择，具有安全性高、起效快速及携带方便的优势，适用于COPD的长期治疗。尽管吸入制剂治疗COPD的效果显著，但在提升患者用药依从性方面仍面临重大挑战。现通过系统梳理COPD患者吸入制剂用药依从性影响因素和改善措施，为优化COPD的疾病管理提供参考依据。
Abstract：Chronic obstructive pulmonary disease(COPD) is a heterogeneous lung disease characterized by persistent respiratory symptoms and airflow limitation. It affects nearly 100 million patients in China and has a high mortality rate worldwide. As a first-line choice for the treatment of COPD, inhalation preparations have the advantages of high safety, rapid onset and portability, and are especially suitable for long-term treatment. Despite the significant effect of inhalation therapy, substantial challenges remain in enhancing patients' medication compliance. Based on the guidelines and existing literature, this paper systematically sorts out the main influencing factors and improvement measures of inhalation medication compliance in COPD patients, aiming to provide a reference for optimizing COPD disease management.
[1]梁振宇,王凤燕,陈子正,等.2023年GOLD慢性阻塞性肺疾病诊断、管理及预防全球策略更新要点解读[J].中国全科医学,2023,26(11):1287.
[2]WANG C,XU J Y,YANG L,et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH] study):a national cross-sectional study[J].Lancet,2018,391(10131):1706.
[3]CHRISTENSON S A,SMITH B M,BAFA DHEL M,et al.Chronic obstructive pulmonary disease[EB/OL].(2022-05-16)[2025-0 1-02].https://www.thelancet.com/journals/lancet/article/PIIS0140-6 73 6(22)00470-6/fulltext.
[4]WORLD HEALTH ORGANIZATION.Projections of mortality and causes of death,2016 and 2060[EB/OL].(2022-02-11)[2025-01-20].https://www.who.int/data/gho/data/themes/topics/topicdetails/GHO/ncd-mortality.
[5]HALPIN D M G,CRINER G J,PAPI A,et al.Global initiative for the diagnosis,management,and prevention of chronic obstructive lung disease.The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2021,203(1):24.
[6]CALVERLEY P M A,ANDERSON J A,CELLI B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356(8):775.
[7]WORLD HEALTH ORGANIZATION.World Health Organization,Department of essential drugs and medicines policy:WHO Workshop on containment of antimicrobial resistance in Europe,26-27 February 2004 in Wernigerode,Germany[J].Bundesgesundheitsbl-Gesundheitsf-Gesundheitsschutz,2005,48(2):221.
[8]BOGART M,STANFORD R H,LALIBERTéF,et al.Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population[J].Int J Chronic Obstr Pulm Dis,2019,14:343.
[9]殷雪梅,赵志刚,闫宇佳,等.中国“三高”慢性病患者药物治疗依从性差异与分布情况[J].中南药学,2023,21(3):706.
[10]SULAIMAN I,CUSHEN B,GREENE G,et al.Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2017,195(10):1333.
[11]PLAZA V,LóPEZ-VI?A A,COSIO B G.Test of adherence to inhalers[J].Arch De Bronconeumologia,2017,53(7):360.
[12]KHDOUR M R,HAWWA A F,KIDNEY J C,et al.Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease(COPD)[J].Eur J Clin Pharmacol,2012,68(10):1365.
[13]LIOU D,KULIK L.Self-efficacy and psychosocial considerationsof obesity risk reduction behaviors in young adult white Americans[J].PLoS One,2020,15(6):e0235219.
[14]ARMOUR C L,LEMAY K,SAINI B,et al.Using the community pharmacy to identify patients at risk of poor asthma control and factors which contribute to this poor control[J].J Asthma,2011,48(9):914.
[15]SAHNI S,TALWAR A,KHANIJO S,et al.Socioeconomic status and its relationship to chronic respiratory disease[J].Adv Respir Med, 2017,85(2):97.
[16]BHATTARAI B,WALPOLA R,MEY A,et al.Barriers and strategies for improving medication adherence among people living with COPD:a systematic review[J].Respir Care,2020,65(11):1738.
[17]KRAUSKOPF K,FEDERMAN A D,KALE M S,et al.Chronic obstructive pulmonary disease illness and medication beliefs are associated with medication adherence[J].COPD J Chronic Obstr Pulm Dis,2015,12(2):151.
[18]王艳,朱素翠,何志萍,等.COPD患者吸入制剂用药信念现状及影响因素分析[J].中国护理管理,2020,20(2):285.
[19]HOMETOWSKA H,SWIATONIOWSKA-LONC N,KLEKOWSKI J,et al.Treatment adherence in patients with obstructive pulmonary diseases[J].Int J Environ Res Public Health,2022,19(18):11573.
[20]DUARTE-DE-ARAúJO A,TEIXEIRA P,HESPANHOL V,et al.COPD:understanding patients'adherence to inhaled medications[J].Int J Chronic Obstr Pulm Dis,2018,13:2767.
[21]BRANDSTETTER S,FINGER T,FISCHER W,et al.Differences in medication adherence are associated with beliefs about medicines in asthma and COPD[J].Clin Transl Allergy,20 17,7(1):39.
[22]LóPEZ-PINTOR E,GRAU J,GONZáLEZ I,et al.Impact of patients'perception of COPD and treatment on adherence and health-related quality of life in real-world:study in 53 community pharmacies[J].Respir Med,2021,176:106280.
[23]周婷婷,韩吉祥.COPD患者合并认知障碍的相关因素及干预措施分析[J].临床医学进展,2023(5):8722.
[24]陈威飞,龚娜.老年慢阻肺患者治疗依从性调查及影响因素研究[J].中国医院统计,2016,23,13(6):436.
[25]王玉,苏丹,林莹,等.慢性阻塞性肺疾病患者使用吸入制剂的依从性分析与评价[J].中国医院用药评价与分析,2020,20(1):114.
[26]PUMAR M I,GRAY C R,WALSH J R,et al.Anxiety and depression—important psychological comorbidities of COPD[J].J Thorac Dis,2014,6(11):1615.
[27]YOHANNES A M,ALEXOPOULOS G S.Depression and anxiety in patients with COPD[J].Eur Respir Rev,2014,23(133):345.
[28]RADELL M L,ABO HAMZAE G, DAGHUSTANI W H,et al.The impact of different types of abuse on depression[J].Depress Res Treat,2021,2021(1):6654503.
[29]梁发存,刘梦如,游姗,等.慢性阻塞性肺疾病病人呼吸困难指数、服药依从性与焦虑水平的相关性[J].循证护理,2022,8(11):1494.
[30]GUNASEKARAN K,MURTHI S,ELANGO K,et al.The impact of diabetes mellitus in patients with chronic obstructive pulmonary disease(COPD)hospitalization[J].J Clin Med,2021,10(2):235.
[31]MARTíNEZ-GESTOSO S,GARCíA-SANZ M T,CARREIRA J M,et al.Impact of anxiety and depression on the prognosis of copd exacerbations[J].BMC Pulm Med,2022,22(1):169.
[32]LECHELER L,RICHTER M,FRANZEN D P,et al.The frequent and underrecognised co-occurrence of acute exacerbated COPD and depression warrants screening:a systematic review[J].Eur Respir Rev,2017,26(144):170026.
[33]DE VOOGD J N,WEMPE J B,KO?TER G H,et al.Depressive symptoms as predictors of mortality in patients with COPD[J].Chest,2009,135(3):619.
[34]郑肖霞,朱晓筱,吴奕帆,等.慢性阻塞性肺疾病患者症状负担与生活质量的相关性研究[J].结核与肺部疾病杂志,2024,5(3):207.
[35]USMANI O S,LAVORINI F, MARSHALL J,et al.Critical inhaler errors in asthma and COPD:a systematic review of impact on health outcomes[J].Respir Res,2018,19(1):10.
[36]O'TOOLE J,KRISHNAN M,RIEKERT K,et al.Understanding barriers to and strategies for medication adherence in COPD:a qualitative study[J].BMC Pulm Med,2022,22(1):98.
[37]CLARK A R,HOLLINGWORTH A M.The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers:implications for in vitro testing[J].J Aerosol Med,1993,6(2):99.
[38]中国医学装备协会呼吸病学专委会吸入治疗与呼吸康复学组,中国慢性阻塞性肺疾病联盟.稳定期慢性气道疾病吸入装置规范应用中国专家共识[J].中华结核和呼吸杂志,2019,42(4):241.
[39]PRICE D B,ROMáN-RODRíGUEZ M,MCQUEEN R B,et al.Inhaler errors in the CRITIKAL study:type,frequency,and association with asthma outcomes[J].J Allergy Clin Immunol Pract,2017,5(4):1071.
[40]NAVAIE M,DEMBEK C, CHO-REYES S,et al.Device use errors with soft mist inhalers:a global systematic literature review and meta-analysis[J].Chron Respir Dis,2020,17:1479973119901234.
[41]CHRYSTYN H,VAN DER PALEN J,SHARMA R,et al.Device errors in asthma and COPD:systematic literature review and metaanalysis[J].NPJ Prim Care Respir Med,2017,27(1):22.
[42]余子慧,万丽红,吴晓冰,等.慢性阻塞性肺疾病病人吸入剂用药依从性与疾病感知的相关性研究[J].循证护理,2023,9(8):1491.
[42]吴秋惠,张桂凡,张晶晶,等.药师主导的干预对哮喘和COPD患者掌握吸入技术的影响[J].医药导报,2019,38(3):333.
[44]JANJUA S,PIKE K C, CARR R,et al.Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease(COPD)[J].Cochrane Database Syst Rev,2021,2021(9):CD013381.
[45]于小杰,杨文明,赵艳敏,等.关于提高慢性气道疾病患者吸入制剂用药依从性的实践与探索[J].中国医院药学杂志,2024,44(2):195.
[46]ZHANG S Y,KING D,ROSEN V M,et al.Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD:a systematic literature review[J].Int J Chronic Obstr Pulm Dis,2020,15:417.
[47]MANNINO D, BOGART M,WU B,et al.Adherence and persistence to once-daily single-inhaler versus multiple-inhalertriple therapy among patients with chronic obstructive pulmonary disease in the USA:a real-world study[J].Respir Med,2022,197:106807.
[48]LEVY M L,DEKHUIJZEN P N R,BARNES P J,et al.Inhaler technique:facts and fantasies.A view from the Aerosol Drug Management Improvement Team(ADMIT)[J].NPJ Prim Care Resp Med,2016,26:16017.
[49]马瑞,董心月,陶田甜,等.慢性阻塞性肺疾病患者用药依从性现状及影响因素分析[J].中国呼吸与危重监护杂志,2023,22(8):533.
[50]NAVAIE M, DEMBEK C,CHO-REYES S,et al.Inhaler device feature preferences among patients with obstructive lung diseases:a systematic review and meta-analysis[J].Medicine,2020,99(25):e20718.
[51]CHOUAID C,GERMAIN N,DE POUVOURVILLE G, et al.Patient preference for chronic obstructive pulmonary disease(COPD)treatment inhalers:a discrete choice experiment in France[J].Curr Med Res Opin,2019,35(5):785.
[52]T?TTENBORG S S, LANGE P,JOHNSEN S P,et al.Socioeconomic inequalities in adherence to inhaled maintenance medications and clinical prognosis of COPD[J].Respir Med,2016,119:160.
[53]IHEANACHO I, ZHANG S Y,KING D,et al.Economic burden of chronic obstructive pulmonary disease(COPD):a systematic literature review[J].Int J Chronic Obstr Pulm Dis,2020,15:439.
[54]PASQUALE C B,CHOATE R,MCCREARY G,et al.Self-reported COPD medication use and adherence in the COPD foundation patient-powered research network[J].Chronic Obstr Pulm Dis J COPD Found,2021,8(4):474.
[55]IHEANACHO I, ZHANG S Y,KING D,et al.Economic burden of chronic obstructive pulmonary disease(COPD):a systematic literature review[J].Int J Chronic Obstr Pulm Dis,2020,15:439.
[56]BUGAJSKI A,FRAZIER S K,MOSER D K,et al.Psychometric testing of the Multidimensional Scale of Perceived Social Support in patients with comorbid COPD and heart failure[J].Heart Lung,2019,48(3):193.
[57]VESTBO J,ANDERSON J A, CALVERLEY P A,et al.Adherence to inhaled therapy,mortality and hospital admission in COPD[J].Thorax,2009,64(11):939.
[58]TUPINáALC?NTARA DE MOREIRA A,RIBEIRO PINTO C,MOREIRA LEMO S A C, et al.Evidence of the association between adherence to treatment and mortality among patients with COPD monitored at a public disease management program in Brazil[J].J Bras Pneumol,2022,48(1):e20210120.
[59]MOLIMARD M,RAHERISON C,LIGNOT S,et al.Chronic obstructive pulmonary disease exacerbation and inhaler device handling:real-life assessment of 2935 patients[J].Eur Respir J,2017,49(2):1601794.
[60]KIM J A,LIM M K, KIM K,et al.Adherence to inhaled medications and its effect on healthcare utilization and costs among high-grade chronic obstructive pulmonary disease patients[J].Clin Drug Investig,2018,38(4):333.
[61]李建,冯芮华,崔月颖,等.我国三级医院药物治疗慢阻肺患者的经济负担分析[J].中国卫生经济,2015,34(9):66.
[62]王洁萍,彭娟,樊必双,等.全身振动训练联合肺康复运动训练在慢性阻塞性肺疾病中的应用研究[J].四川医学,2021,42(8):824.
[63]李建,冯芮华,崔月颖,等.我国三级医院药物治疗慢阻肺患者的经济负担分析[J].中国卫生经济,2015,34(9):66.
[64]胡相悦,范耀菊.基于指南构建肺康复运动方案对慢性阻塞性肺疾病稳定期患者运动耐力、衰弱状况和生活质量的影响研究[J].实用心脑肺血管病杂志,2021,29(2):64.
[65]KUNIK M E, BRAUN U,STANLEY M A, et al.One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease[J].Psychol Med,2001,31(4):717.
[66]陈典,隆寰宇,李姝润,等.2024年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J].中国全科医学,2024,27(13):1533.
[67]VAN DER PALEN J,THOMAS M,CHRYSTYN H,et al.A randomised open-label cross-over study of inhaler errors,preference and time to achieve correct inhaler use in patients with COPD or asthma:comparison of ELLIPTA with other inhaler devices[J].NPJ Prim Care Respir Med,2016,26:16079.
[68]CAPLIN M,SAUNDERS T.Utilizing teach-back to reinforce patient education:a step-by-step approach[J].Orthop Nurs,2015,34(6):365.
[69]李萍,黄砚萍,王冰,等.Teach-back健康教育对COPD稳定期患者知信行的影响[J].川北医学院学报,2021,36(2):265.
[70]陈健聪,吴锡平.糠酸氟替卡松/维兰特罗治疗慢性阻塞性肺疾病的有效性与安全性[J].国际呼吸杂志,2018(7):549.
[71]丛晓飞,张强.慢性阻塞性肺疾病患者初始应用LABA/LAMA与ICS/LABA的依从性以及急性加重情况比较[J].实用药物与临床,2024,27(1):30.
[72]张振香,何福培,张春慧,等.慢性病共病患者服药依从性潜在类别及其影响因素分析[J].中国全科医学,2022,25(31):3904.
[73]谢瑶,李涓玉,王习竹,等.格林模式在慢性病健康管理中的应用进展[J].职业与健康,2024,40(2):279.
[74]周虹.PRECEDE护理模式在慢性阻塞性肺疾病合并支气管扩张病人中的应用效果[J].循证护理,2024,10(7):1276.
[75]李燕,徐小艳,任旭,等.PRECEDE-PROCEED模式在慢性疾病患者健康行为中的研究进展[J].当代护士(下旬刊),2024,31(3):9.
[76]卜艳珍.基于格林模式的护理干预在老年COPD患者肺康复锻炼知信行的应用研究[D].呼和浩特:内蒙古医科大学,2021.
[77]张蓓蓓,钱剑,申琴.饮食指导联合PRECEDE模式护理对慢性阻塞性肺炎患者肺功能及血清蛋白的影响[J].河北医药,2020,42(21):3350.
[78]许娟,刘义兰,邓群.稳定期COPD患者自我效能与家庭关怀度的相关性研究[J].上海护理,2018,18(11):36.
[79]胡佳,王芳,冯芮华,等.不同卫生体制国家和地区慢性阻塞性肺疾病医防融合经验与启示[J].中国公共卫生,2023,39(6):811.
基本信息:
DOI：10.19577/j.1007-4406.2025.11.016
中图分类号:R563.9
引用信息:
[1]官梦霞,姜黎,刘天虎,等.慢性阻塞性肺疾病患者吸入制剂用药依从性影响因素和改善措施的研究进展[J].中国临床药学杂志,2025,34(11):875-880.DOI:10.19577/j.1007-4406.2025.11.016.
基金信息:
成都市医学科研课题（编号2024203）; 成都医学院研究生科研创新基金项目（编号YCX2024-03-13）;成都医学院科技基金资助科研项目（编号CYSYB20-09）; 中国药学会全国医药信息网科普研究项目（编号CMEI2022KPYJ00271）
2025-11-24
2025-11-24